12:00 AM
 | 
Mar 11, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Perjeta pertuzumab regulatory update

The European Commission approved an MAA from Roche for Perjeta pertuzumab to treat previously untreated HER2-positive metastatic breast cancer. The product is approved in combination with Herceptin trastuzumab and docetaxel to treat adults with HER2-positive metastatic or locally recurrent unresectable breast cancer who have not received previous...

Read the full 225 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >